CR20110339A - Compuestos útiles para inhibir chk1 - Google Patents

Compuestos útiles para inhibir chk1

Info

Publication number
CR20110339A
CR20110339A CR20110339A CR20110339A CR20110339A CR 20110339 A CR20110339 A CR 20110339A CR 20110339 A CR20110339 A CR 20110339A CR 20110339 A CR20110339 A CR 20110339A CR 20110339 A CR20110339 A CR 20110339A
Authority
CR
Costa Rica
Prior art keywords
useful compounds
inhibit chk1
chk1
inhibit
useful
Prior art date
Application number
CR20110339A
Other languages
English (en)
Inventor
Francine S Farouz
Ryan Coatsworth Holcomb
Ramesh Kasar
Steven Scott Myers
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CR20110339A publication Critical patent/CR20110339A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a un compuesto aminopirazol, o una sal del mismo farmacéuticamente aceptable o un solvato de la sal, que inhibe a Chk1 y es útil en el tratamiento de cáncer.
CR20110339A 2008-12-17 2011-06-17 Compuestos útiles para inhibir chk1 CR20110339A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13817608P 2008-12-17 2008-12-17

Publications (1)

Publication Number Publication Date
CR20110339A true CR20110339A (es) 2011-09-14

Family

ID=42079067

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110339A CR20110339A (es) 2008-12-17 2011-06-17 Compuestos útiles para inhibir chk1

Country Status (38)

Country Link
EP (1) EP2379532B1 (es)
JP (1) JP5705743B2 (es)
KR (1) KR101301777B1 (es)
CN (1) CN102245597B (es)
AR (1) AR074471A1 (es)
AU (1) AU2009333433B2 (es)
BR (1) BRPI0922468A2 (es)
CA (1) CA2746423C (es)
CL (1) CL2011001463A1 (es)
CO (1) CO6382122A2 (es)
CR (1) CR20110339A (es)
CY (1) CY1113930T1 (es)
DK (1) DK2379532T3 (es)
DO (1) DOP2011000185A (es)
EA (1) EA018118B1 (es)
EC (1) ECSP11011136A (es)
ES (1) ES2401558T3 (es)
HK (1) HK1160110A1 (es)
HN (1) HN2011001446A (es)
HR (1) HRP20130167T1 (es)
IL (1) IL213160A (es)
JO (1) JO2886B1 (es)
MA (1) MA32901B1 (es)
MX (1) MX2011006603A (es)
MY (1) MY156998A (es)
NZ (1) NZ593440A (es)
PA (1) PA8850801A1 (es)
PE (1) PE20120077A1 (es)
PL (1) PL2379532T3 (es)
PT (1) PT2379532E (es)
RS (1) RS52739B (es)
SG (1) SG172222A1 (es)
SI (1) SI2379532T1 (es)
TN (1) TN2011000298A1 (es)
TW (1) TWI436996B (es)
UA (1) UA101998C2 (es)
WO (1) WO2010077758A1 (es)
ZA (1) ZA201103946B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314108B2 (en) * 2008-12-17 2012-11-20 Eli Lilly And Company 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts
JO3145B1 (ar) * 2010-11-08 2017-09-20 Lilly Co Eli مركبات مفيدة لتثبيط chk1
GB201402277D0 (en) 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
TWI725041B (zh) * 2015-07-23 2021-04-21 美商美國禮來大藥廠 用於治療神經母細胞瘤及/或軟組織肉瘤之chk1/2抑制劑
TWI627168B (zh) * 2015-12-07 2018-06-21 美國禮來大藥廠 (s)-乳酸鹽
WO2017105982A1 (en) * 2015-12-15 2017-06-22 Eli Lilly And Company Combination therapy for cancer
SI3411036T1 (sl) * 2016-02-04 2022-03-31 Pharmaengine, Inc. 3,5-disubstituirani pirazoli, uporabni kot kontrolne točke inhibitorjev kinaze 1 (CHK1), ter njihovi pripravki in uporaba
KR20190130621A (ko) 2017-03-31 2019-11-22 시애틀 지네틱스, 인크. Chk1 저해제와 wee1 저해제의 조합물
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
JP7260718B2 (ja) * 2019-11-29 2023-04-18 メッドシャイン ディスカバリー インコーポレイテッド ジアザインドール誘導体及びそのＣｈｋ１阻害剤としての使用
WO2021119236A1 (en) 2019-12-10 2021-06-17 Seagen Inc. Preparation of a chk1 inhibitor compound
US11564920B2 (en) 2020-11-30 2023-01-31 Sumitomo Pharma Co., Ltd. 5-heteroaryl-1H-pyrazol-3-amine derivative
JP7082256B1 (ja) * 2020-11-30 2022-06-07 住友ファーマ株式会社 ５－ヘテロアリール－１ｈ－ピラゾール－３－アミン誘導体
KR20240021188A (ko) 2021-05-27 2024-02-16 바운드리스 바이오, 인크. 체크포인트 키나제 1(chk1) 억제제 및 그의 용도
GB202107924D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd A pharmaceutical salt
GB202107932D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd Preparation of a CHK1 Inhibitor Compound
WO2023120696A1 (ja) * 2021-12-24 2023-06-29 住友ファーマ株式会社 二環性骨格を有する１ｈ－ピラゾール－３－アミン誘導体
WO2023229032A1 (ja) * 2022-05-27 2023-11-30 住友ファーマ株式会社 免疫チェックポイント阻害剤に対して治療抵抗性を示すがんの治療薬
GB202213792D0 (en) 2022-09-21 2022-11-02 Benevolentai Bio Ltd New compounds and method

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040034038A1 (en) * 2002-08-13 2004-02-19 Goaquan Li Urea kinase inhibitors
JP2006528661A (ja) * 2003-07-25 2006-12-21 ファイザー・インク アミノピラゾール化合物およびｃｈｋ１阻害剤としての使用
WO2008117050A1 (en) * 2007-03-27 2008-10-02 Astrazeneca Ab Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
US20090270418A1 (en) * 2008-01-09 2009-10-29 Marianne Sloss Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith

Also Published As

Publication number Publication date
ES2401558T3 (es) 2013-04-22
HK1160110A1 (en) 2012-08-10
MY156998A (en) 2016-04-15
SI2379532T1 (sl) 2013-05-31
WO2010077758A1 (en) 2010-07-08
ECSP11011136A (es) 2011-07-29
DK2379532T3 (da) 2013-03-18
CO6382122A2 (es) 2012-02-15
IL213160A0 (en) 2011-07-31
PE20120077A1 (es) 2012-02-06
EP2379532A1 (en) 2011-10-26
HN2011001446A (es) 2013-08-05
MX2011006603A (es) 2011-09-27
JP5705743B2 (ja) 2015-04-22
AR074471A1 (es) 2011-01-19
CN102245597A (zh) 2011-11-16
JO2886B1 (en) 2015-03-15
KR20110084539A (ko) 2011-07-25
EP2379532B1 (en) 2013-02-20
BRPI0922468A2 (pt) 2020-08-04
IL213160A (en) 2013-12-31
TWI436996B (zh) 2014-05-11
JP2012512249A (ja) 2012-05-31
CN102245597B (zh) 2014-04-16
RS52739B (en) 2013-08-30
CA2746423C (en) 2014-01-14
PA8850801A1 (es) 2010-07-27
CY1113930T1 (el) 2016-07-27
NZ593440A (en) 2013-02-22
TN2011000298A1 (en) 2012-12-17
AU2009333433A1 (en) 2011-06-30
HRP20130167T1 (hr) 2013-03-31
EA018118B1 (ru) 2013-05-30
DOP2011000185A (es) 2017-12-15
CL2011001463A1 (es) 2012-01-20
UA101998C2 (ru) 2013-05-27
KR101301777B1 (ko) 2013-08-30
EA201170834A1 (ru) 2011-12-30
CA2746423A1 (en) 2010-07-08
TW201029994A (en) 2010-08-16
SG172222A1 (en) 2011-07-28
MA32901B1 (fr) 2011-12-01
AU2009333433B2 (en) 2012-06-14
PL2379532T3 (pl) 2013-07-31
PT2379532E (pt) 2013-03-25
ZA201103946B (en) 2012-10-31

Similar Documents

Publication Publication Date Title
CR20110339A (es) Compuestos útiles para inhibir chk1
PE20151654A1 (es) Inhibidores de cdc7
PA8841901A1 (es) Compuestos orgánicos
CO2018013293A2 (es) Derivados de pirazolopirimidina como inhibidor de quinasa
NI200900184A (es) Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer.
ECSP14017584A (es) Compuestos inhibidores de raf
UY33498A (es) Combinaciones de inhibidores de quinasas para el tratamiento de cancer
PA8852901A1 (es) Inhibidores de proteina cinasa
PA8740901A1 (es) Compuestos organicos
DOP2009000243A (es) Inhibidores de piridopirimidinona de pi3k-alfa en el tratamiento del cancer
UY32730A (es) Inhibidores de cyp17
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
CR20110560A (es) Métodos de tratamiento para tumores sólidos
CR20140036A (es) Compuesto inhibidor de la señalización de la trayectoria notch
CR10277A (es) Pirazolquinolonas como potentes inhibidores de parp
GT201200038A (es) Composicion para tratar la fibrosis quistica
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
HN2011003403A (es) Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas
DOP2008000053A (es) Inhibidores de akt(proteinas cinasa b)
CL2017001209A1 (es) Inhibidor de cinasa aurora a
GT201300263A (es) Combinación de un inhibidor de cinasa de fosfatidilinositol-3 (pi3k) y un inhibidor de mtor